

|            |        |      |         |      |     |         |      |     |
|------------|--------|------|---------|------|-----|---------|------|-----|
| <b>CV%</b> | 24.3   | 37.3 | 11.8    | 14.4 | 0.0 | 12.9    | 0.0  | 4.6 |
| <b>n</b>   | 6.0    | 6.0  | 6.0     | 6.0  | 6.0 | 6.0     | 6.0  | 6.0 |
| <b>Min</b> | 3559.4 | 0.75 | 16422.1 | 3.1  | 0.2 | 18136.0 | 12.0 | 0.8 |
| <b>Max</b> | 7012.2 | 2.50 | 21758.2 | 4.5  | 0.2 | 24428.4 | 12.0 | 0.9 |

### Statistical Evaluation of Results

The primary endpoint pharmacokinetic parameters of diacerein 50 mg single oral dose were determined prior and post the administration of 500 mg glucosamine twice daily over a period of 5 days to study subjects; however, the level of change in the primary pharmacokinetic parameters was insignificant ( $p > 0.05$ ) as seen in table 10.